| __timestamp | Alnylam Pharmaceuticals, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 40786000 |
| Thursday, January 1, 2015 | 60610000 | 47876000 |
| Friday, January 1, 2016 | 89354000 | 52035000 |
| Sunday, January 1, 2017 | 199365000 | 55348000 |
| Monday, January 1, 2018 | 382359000 | 65276000 |
| Tuesday, January 1, 2019 | 479005000 | 82720000 |
| Wednesday, January 1, 2020 | 588420000 | 89118000 |
| Friday, January 1, 2021 | 620639000 | 181193000 |
| Saturday, January 1, 2022 | 770658000 | 174078000 |
| Sunday, January 1, 2023 | 795646000 | 184232000 |
| Monday, January 1, 2024 | 975526000 |
Unlocking the unknown
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Alnylam Pharmaceuticals and Veracyte, Inc. have shown contrasting trends in their SG&A expenses over the past decade. From 2014 to 2023, Alnylam's SG&A costs surged by over 1,600%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Veracyte's expenses grew by approximately 350%, indicating a more conservative approach.
Alnylam's expenses peaked in 2023, reaching nearly four times that of Veracyte's. This disparity highlights Alnylam's strategy of prioritizing growth, while Veracyte focuses on cost efficiency. As investors and stakeholders evaluate these companies, understanding their financial strategies provides insight into their long-term sustainability and market positioning.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Veracyte, Inc.
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Veracyte, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Veracyte, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Veracyte, Inc. or Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Veracyte, Inc. vs Mesoblast Limited
Comparing SG&A Expenses: Veracyte, Inc. vs Xencor, Inc. Trends and Insights